David Uehling

I have spent much of my career as medicinal chemist, working for GlaxoSmithKline or its legacy companies for over 19 years. While at GSK, I was involved in a number of therapeutic areas particularly oncology and metabolic diseases. I have contributed to programs that have led to the discovery of clinical candidates, and was the chemistry project leader for the marketed B-Raf inhibitor dabrafenib. Since 2009, I have pursued drug discovery in the government not-for-profit setting at the Ontario Institute for Cancer Research, leading early efforts to validate and progress early stage projects.